SFX by Ex Libris Inc.

Title:	Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Source:	Nature [0028-0836] Pastor, F yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Gu, W. "Distinct Argonaute-Mediated 22G-RNA Pathways Direct Genome Surveillance in the C. elegans Germline." Molecular cell 36.2 (2009): 231-244.
description	2.	Smith, L. "NanotechnologyMolecular robots on the move." Nature 465.7295 (2010): 167-168.
description	3.	Ribas, A. "Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles." Nature advance online publication.7291 (2010): 1067-1070.
description	4.	"Cancer drug development: Targeted tumour take-out." Nature 462.7276 (2009): 961-961.
description	5.	Oney, S. "Development of universal antidotes to control aptamer activity." Nature Medicine 15.10 (2009): 1224-1228.
description	6.	Davis, Mark E. "The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic." Molecular pharmaceutics 6.3 (2009): 659-668.
description	7.	Castanotto, D. "The promises and pitfalls of RNA-interference-based therapeutics." Nature 457.7228 (2009): 426-433.
description	8.	Oh, Yu-Kyoung G. "siRNA delivery systems for cancer treatment." Advanced Drug Delivery Reviews 61.10 (2009): 850-862.
description	9.	Whitehead, Daniel G A. "Knocking down barriers: advances in siRNA delivery." Nature reviews. Drug discovery 8.2 (2009): 129-38.
description	10.	Mello, Craig C. "The Argonaute CSR-1 and Its 22G-RNA Cofactors Are Required for Holocentric Chromosome Segregation." Cell 139.1 (2009): 123-134.
description	11.	Rolland, O. "Dendrimers and nanomedicine: multivalency in action." New journal of chemistry 33.9 (2009): 1809-1824.
description	12.	Rusconi, Shahid M A. "Aptamers: an emerging class of therapeutics." Annual review of medicine 56.1 (2005): 555-83.
description	13.	Moatti, J. "Les modèles d'analyse des comportements à risque face à l'infection à VIH: Une conception trop étroite de la rationalité." Population 48.5 (1993): 1505-1534.
description	14.	McCarthy, M. "Treatment triggers targeted tumour infarcts in mice." Lancet 349.9047 (1997): 259-259.
description	15.	Loadman, P. "Anticancer Drug Development." British Journal of Cancer 86.10 (2002): 1665-1666.
description	16.	W. Humphrey, W. "Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer." Journal of the National Cancer Institute 103.16 (2011): 1222-1226.
description	17.	"The Development of a Cancer Drug." New York Times (2009): 2-.
description	18.	Stadtfeld, M. "Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells." Nature 465.7295 (2010): 175-181.
description	19.	Griffith, O. "Electronic Properties of Pentacene versus Triisopropylsilylethynyl-Substituted Pentacene: Environment-Dependent Effects of the Silyl Substituent." Journal of the American Chemical Society 132.2 (2010): 580-586.
description	20.	Montemerlo, M. "Junior: The Stanford entry in the Urban Challenge." Journal of Field Robotics 25.9 (2008): 569-597.